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Abstract
Stem cell therapy is a promising strategy to treat neurodegenerative diseases, traumatic brain injury, and stroke. For stem
cells to progress towards clinical use, the risks associated with invasive intracranial surgery used to deliver the cells to the
brain, needs to be reduced. Here, we show that MRI-guided focused ultrasound (MRIgFUS) is a novel method for non-
invasive delivery of stem cells from the blood to the brain by opening the blood brain barrier (BBB) in specific brain regions.
We used MRI guidance to target the ultrasound beam thereby delivering the iron-labeled, green fluorescent protein (GFP)-
expressing neural stem cells specifically to the striatum and the hippocampus of the rat brain. Detection of cellular iron
using MRI established that the cells crossed the BBB to enter the brain. After sacrifice, 24 hours later, immunohistochemical
analysis confirmed the presence of GFP-positive cells in the targeted brain regions. We determined that the neural stem
cells expressed common stem cell markers (nestin and polysialic acid) suggesting they survived after transplantation with
MRIgFUS. Furthermore, delivered stem cells expressed doublecortin in vivo indicating the stem cells were capable of
differentiating into neurons. Together, we demonstrate that transient opening of the BBB with MRIgFUS is sufficient for
transplantation of stem cells from the blood to targeted brain structures. These results suggest that MRIgFUS may be an
effective alternative to invasive intracranial surgery for stem cell transplantation.
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Introduction
Significant progress in the field of stem cell therapy for
neurodegenerative diseases, brain injuries, and ischemic stroke
highlights its great potential and remaining challenges [1,2].
One of the important findings is that neural stem cells
transplanted into the brain can survive long term and exert
positive effects on the symptoms of disease [3]. For example, in
a series of open-label clinical trials where human fetal stem cells
were grafted into patients with Parkinson’s disease, significant
improvements in motor function and timing were observed
[3–5].
In an animal model of Parkinson’s disease, grafted mesenchy-
mal cells have a neuroprotective effect on remaining dopaminergic
neurons [6]. Also, grafted neural stem cells integrated into the
brain and were found to restore motor function [7]. Recently,
neural stem cell transplantation was shown to improve cognition in
mouse models of Alzheimer’s disease [8]. Furthermore, stem cells
have been shown to dramatically improve functional recovery in
models of ischemic stroke [1].
One major limitation for the translation of these potential stem
cell therapies to clinical practice is the risk associated with invasive
cell transplantation methods and the limitation of unwanted
repeated surgeries. Intracerebral transplantation of stem cells is the
most commonly used method of stem cell delivery to the brain.
There are many risks associated with this invasive method, such as
risks of surgery, direct tissue trauma causing inflammation and
edema [9] as well as graft rejection from immunological re-
sponse [10]. Other methods to circumvent the risks of surgical
transplantation such as intranasal delivery have been proposed
but they are untargeted, requiring the cells to migrate to the
appropriate brain regions [11]. Intraarterial infusion of hyperos-
motic solutions like mannitol, effectively disrupt the BBB and are a
potential method for improving stem cell delivery [12]. However,
these agents may have serious side effects as they allow potentially
cytotoxic compounds present in the blood direct access to the
entire CNS for long periods of time.
To circumvent the problems associated with invasive surgeries
and to provide localized delivery of stem cells to specific brain
regions, we investigated the potential of MRIgFUS to deliver stem
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technology have been used to transiently increase the permeability
of the BBB, allowing agents to cross from the blood stream to the
brain [13]. FUS applies concentrated acoustic energy on a focal
spot measuring a few millimeters in diameter [13]. A micro-
bubble contrast agent is administered systemically and when
FUS is applied transcranially to a specific location, the circulating
microbubbles begin to oscillate. This leads to changes in the blood
vessel wall and a transient increase in the permeability of the BBB
[14]. Previous work has shown that transient changes in BBB
permeability by FUS allows entry of chemotherapeutics and
therapeutic antibodies to targeted areas of the brain [15,16].
In this study, we demonstrate that FUS-induced BBB
disruption allows neural stem cells to move from the blood
stream into the brain tissue. Furthermore, using MRI guidance,
we were able to target specific, clinically relevant structures for
BBB disruption as well as confirm the entry of iron-loaded stem
cells. Finally, our results show that the neural stem cells survived
well up to 24 hours after FUS indicating that this technique is a
powerful option for non-invasive, targeted delivery of neural
stem cells to the brain.
Results
MRIgFUS increases BBB permeability and permits entry of
neural stem cells to the brain
A schematic of the experimental setup is depicted in Fig. 1A.
Briefly, axial, coronal and sagittal T2-weighted MR images were
used to precisely target the regions of the striatum and the
hippocampus in the left hemisphere of adult rats. Four target
points creating a 1 mm square were chosen in each of the striatum
and the hippocampus. Microbubbles were injected intravenously
immediately prior to the onset of sonication (558 kHz transducer,
0.24 MPa estimated in situ pressure, 1 ms bursts, 1 Hz pulse
repetition frequency, 120 s total exposure duration) according to
Jorda ˜o et al [16]. Following the sonication, MR contrast agent
was injected through the tail vein to monitor changes in BBB
permeability in contrast-enhanced T1-weighted images. Enhance-
ment was observed in the targeted regions of the left striatum
(Fig. 1B) and the left hippocampus (Fig. 1C). Analysis of the T1-
weighted images revealed that the levels of contrast-enhancement
ranged from 18–30% except for one animal where enhancement
in the striatum reached 41% (Table S1). GFP-tagged neural stem
cells were injected through a catheter in the carotid artery. In
order to visualize the translocation of the cells using MRI, we
incorporated superparamagnetic iron oxide into the neural
stem cells prior to the experiment. The percentage of stem cells
containing iron oxide ranged from 80–93%. The addition of the
iron oxide did not affect the survival or proliferation rates of the
cells in culture (Figure S1). We evaluated whether we could
confirm entry of iron-loaded stem cells into the brain using fast
gradient echo (FGRE) imaging sequences (TE: 20, TR:30, flip
angle:30). We found disturbances in the FGRE images in the
region of sonication after injection of iron-loaded cells (Fig. 1D)
which were absent prior to sonication (Fig. 1E). These distur-
bances were specific to the left hemisphere and absent in animals
where the injected cells were not iron-labeled or when the animal
was not sonicated. Together the data indicate that MRI may be
Figure 1. MRIgFUS increases BBB permeability to allow neural stem cells into the brain. A) T2-weighted MR images were taken in all 3
planes (sagittal, coronal and axial) and used to choose precise coordinates in the left striatum and left hippocampus for sonication with FUS. Contrast
enhanced T1-weighted MR images were used to confirm increased BBB permeability in the striatum (B) and the hippocampus (C) prior to injection of
neural stem cells into the carotid artery. Fast gradient echo (FGRE) sequences taken before (D) and 15 min after sonication (E) were used to confirm
the entry of iron-labeled neural stem cells. Dark spots (red arrow) in the MR images taken after cell injection were used to confirm the presence of
iron-labeled cells in the tissue.
doi:10.1371/journal.pone.0027877.g001
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and to evaluate the success of MRIgFUS delivery. In future
studies, the use of iron-oxide particles will assist in tracking the
survival and the migration of stem cells transplanted by MRIgFUS
over time, as previously established in animal models and human
patients [17].
Stem cells are present in the brain 24 hours after
translocation through the BBB
Animals were recovered and kept for up to 24 hours prior to
sacrifice. We then evaluated the success of MRIgFUS for delivery
of neural stem cells to the brain using immunohistochemistry on
brain sections from animals in each of 3 groups: 1) MRIgFUS +
stem cells (n=8), 2) stem cells alone (n=4) and 3) MRIgFUS alone
(n=2). GFP-positive stem cells were identified in the left
hemisphere of all animals administered stem cells following
MRIgFUS (Fig. 2A,B) and were not observed in the right
hemisphere, which was untreated with MRIgFUS, (Fig. 2C,D)
or in animals given stem cells but no sonication. GFP-positive cells
were found in the left hippocampus as well and exhibited a
neuronal-like phenotype. The cells were mainly located in the
granular layer of the dentate gryus and the pyramidal layer of the
CA1 region (Fig. 2E,F). We estimated the total number of stem
cells delivered to the brain by counting the number of GFP
positive cells in a 1 mm61 mm region of interest at the
hippocampus. We analysed the section from each animal which
was determined to be the centre of the sonicated region. Our
analysis revealed that 3268.7 cells were successfully delivered per
mm
2 region of the brain (n=8).
Stem cells express neuronal markers in vivo
We demonstrated that GFP-positive cells in the brain also
expressed the stem cell markers polysialic acid (Fig. 3A) and nestin
(Fig. 3B,C) after 4 hours in vivo. The staining pattern was similar to
that observed in vitro (Figure S1). The MRIgFUS treatment alone
did not induce obvious nestin or polysialic acid expression in non-
GFP expressing cells at 4 or 24 hours. It has been reported that
neural stem cells in vivo express neuronal or glial markers within 1–
3 days [18], thus, we evaluated the expression of doublecortin, a
marker of immature neurons, and glial fibrillary acidic protein
(GFAP), a marker of astrocytes. At 24 hours post-sonication, we
found GFP-positive cells which exhibited a neuronal phenotype
(Fig. 3C) and some which also expressed the neuronal marker,
doublecortin (Fig. 3D). We did not find any evidence of GFP-
positive cells expressing GFAP 24 hours after sonication. Many
stem cells express astrocytic markers when they are capable of
differentiating into both mature neurons and astrocytes however
the neural stem cells used in these experiments did not express
GFAP in vitro indicating that the cells are programmed for
neuronal lineage. These results suggest that the stem cells survive
after transplantation with MRIgFUS and that they are capable of
differentiating into a neuronal lineage in vivo.
Histological evaluation showed minimal tissue damage
following MRIgFUS
Post-mortem histology identified the presence of extravasated
red blood cells in the tissue at the site of sonication (Fig. 4). We did
not observe any evidence of lesioning or other severe damage to
the tissue as has been previously reported [19].
Discussion
Stem cells have shown great potential for treatment of a variety
of brain disorders including neurodegenerative diseases and
ischemic stroke [1–3]. Currently, the most common method for
stem cell delivery to the brain is using intracerebral transplantation
which has many associated risks. Here, we present data showing
that FUS can alter the BBB to allow neural stem cells to move
from the blood stream into the brain parenchyma, providing an
alternative to intracerebral transplantation.
Using MRI guidance, we demonstrate that the FUS energy can
be concentrated to a region of interest thereby allowing the stem
cells to be delivered to a single brain structure, sparing the
surrounding brain tissue. In this study we delivered cells to the left
striatum and the left hippocampus which are regions of clinical
interest for treatment of Huntington’s and Alzheimer’s disease,
respectively. MRIgFUS is advantageous to other methods off BBB
opening, such as hyperosmotic agents or vasodilators, which cause
widespread BBB permeabilization and have had limited success in
translocation of stem cells [12,19]. The accuracy of MRIgFUS is
similar to stereotaxic injection and causes limited tissue damage.
Our histological analysis revealed some red blood cells present in
tissue around the areas of sonication. Our previous studies in
Figure 2. MRIgFUS allows GFP-expressing stem cells to cross
the BBB and enter the brain parenchyma. Anti-GFP antibodies
were used to detect stem cells in the brain tissue after delivery by
MRIgFUS. GFP-positive cells could be detected in the left striatum (A,B)
but not in the right, untreated striatum (C,D) indicating the cells were
delivered only to the targeted regions. In the hippocampus, stem cells
were found in the pyramidal cell layer of the CA1 region (E, arrow) and
the granular layer of the dentate gyrus (F, arrow). Scale bars: A,C,E =
100 mm, B,D,F = 10 mm.
doi:10.1371/journal.pone.0027877.g002
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cell extravasation do not produce long term damage [20]. Since
the average diameter of the neural stem cells is approximately
10 mm, we predict that the extent of BBB opening required to
allow entry of the stem cells will result in some red blood cell
extravasation. We suspect that most of the delivered stem cells
enter the brain via widened tight junctions created by FUS, similar
to the red blood cells. However, previous reports have suggested
that stem cells can also cross the BBB via induced paracellular
routes [21]. It will be imperative in future studies to optimize FUS
parameters to strike a balance between maximizing the entry of
stem cells to the brain and minimizing red blood cell extravasation
caused by MRIgFUS.
Previous work has used MRI to monitor the survival and
migration of iron-labeled cells in the brain [17,22]. Here, we
investigated whether we could FGRE MR imaging sequences
which are sensitive to iron and blood products, to confirm cell
delivery after FUS. Indeed, we observed hypointense regions on
the images in the sonicated regions after iron-loaded stem cells
were delivered with FUS. We did not see corresponding
hypointense regions on images from animals who received non-
iron loaded stem cells suggesting that the hypointense regions are
due to the presence of iron-loaded stem cells in the brain.
However, as mentioned, FGRE imaging sequences are also
sensitive to the presence of blood and our histological analysis
shows red blood cell extravasation occurs at the FUS site.
Therefore, we cannot irrefutably conclude that the hypointense
region of the FGRE images is the stem cells. Future work to
minimize the extent of red blood cell extravasation during stem
cell delivery would improve the use of MRI to track cell entry.
One of the concerns arising from intracerebral transplantation
of neural stem cells is the immunological reaction and inflamma-
tion which can lead to graft rejection [9]. The immunological
reaction caused by transplantation of cells with MRIgFUS has not
been fully evaluated. In our previous work, we observed edema
(detected on T2-weighted MRI images after sonication) when
enhancement on T1-weighted images was greater than 30% [23].
In the current study, we demonstrated that stem cells entered the
brain in animals showing enhancement of ,30% suggesting that
edema can be minimized by controlling the sonication parameters
and limiting the T1-weighted enhancement. However, the extent
of inflammatory and immunological reaction due to MRIgFUS
still requires investigation. The increase in BBB permeability has
been shown to be transient and reversible [14], so it is reasonable
to expect that repeated treatments for multiple transplantations is
possible. The use of MRIgFUS to deliver small volumes of stem
cells over several weeks or months may decrease the insult of
transplantation to the brain, reduce the inflammatory response
and improve cell survival in vivo.
We demonstrate that MRIgFUS is a powerful technique that
may be useful for delivery of stem cells for treatment of ischemic
stroke. Specifically, intraarterial delivery of stem cells has shown
great potential as a stroke treatment but there is great variability in
the number of cells which actually arrive at the site of damage
[24]. By combining intraarterial delivery of stem cells with
MRIgFUS, the permeability of the BBB in the infarcted region
can be increased thereby improving the number of cells with
access to the ischemic penumbra. In this study, we chose the
carotid artery as the preferred entry point in our rat model
however catheterization of the femoral artery is a routine clinical
practice and could be used for translation of MRIgFUS to the
clinic.
Overall, the delivery of stem cells to the brain with FUS shows
promise and it represents several advantages compared to
traditional stereotaxic, intracerebral transplantation of cells into
the brain. First, FUS does not require invasive intracranial
surgery, limiting the associated risks of infection and hemorrhage.
Second, the increase in BBB permeability with FUS is transient
and non-invasive, indicating it is plausible that patients could
receive multiple treatments over their lifetime to improve the
outcome of the therapy. Third, for targeting multiple sites, FUS
can be used to deliver cells to the striatum and the hippocampus,
or other regions, in the same session and with less damage relative
to needle implantation. Cell delivery with FUS is targeted and can
be used to avoid the distribution of cells along the needle track as
often occurs with intracerebral transplantation [1]. Finally, MRI
provides excellent soft tissue contrast and therefore can be used to
Figure 3. GFP-positive cells express markers of stem cells and
immature neurons in vivo. Immunohistochemistry revealed GFP-
positive cells in the brain expressed polysialic acid (A, red) and nestin (B,
red) after 4 hours. After 24 hours, nestin positive cells exhibit a
neuronal phenotype (C) and a few GFP-positive cells expressed
doublecortin, a marker of immature neurons (D, red). Scale bars: 10 mm.
doi:10.1371/journal.pone.0027877.g003
Figure 4. Histological analysis reveals limited tissue damage.
Brain sections were processed for H&E according to standard
procedures. Red blood cell extravasation was observed in the sonicated
regions (inset). There was no indication of lesioning or permanent tissue
damage. Scale bars = 2000 mm, inset = 100 mm.
doi:10.1371/journal.pone.0027877.g004
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that stem cells have to migrate in vivo. Inadequate cell migration
has been a key problem in human patients [25] and thus may limit
the clinical relevance of methods where the cells must migrate
large distances, such as intranasal cell delivery [11].
The results shown here suggest that MRIgFUS is an effective
tool for delivery of neural stem cells to targeted regions of the
brain. MRIgFUS is non-invasive, results in minimal tissue damage
and has potential for repeated cell delivery. MRIgFUS may be the
key to improving cell delivery to the brain and leading to
improvements in stem cell therapy in the clinical setting.
Materials and Methods
Animals
Sprague Dawley rats (200–250 g) with a vascular catheter in the
left common carotid artery were received from Charles River
Laboratories (Wilmington MA). All experimental procedures were
approved by the Animal Care Committee of Sunnybrook
Research Institute (Protocol 290) and conformed to the guidelines
set by the Canadian Council on Animal Care and the Animals for
Research Act of Ontario.
Cell culture
GFP-transfected embryonic cortical neural progenitor cells were
obtained from Millipore and grown as adherent monolayers on
polyornithine (10 mg/mL] and laminin (5 mg/mL) coated Petri
dishes. The cells were grown in neural stem cell defined media
(supplemented with basic fibroblast growth factor (20 ng/mL),
epidermal growth factor (20 ng/mL) and heparin (2 mg/mL)).
Superparamagnetic iron oxide (5 mg; Sigma Aldrich) was added to
the stem cell media 24 hours prior to the beginning of the
experiment. The effect of the uptake of iron cells on cell survival
and proliferation was monitored in concurrent in vitro experiments.
Cultures containing iron oxide were grown for up to 48 hours. At
0, 24 and 48 hours, cells were collected with Accutase, centrifuged
and counted with a hemocytometer. Trypan blue was used to
exclude dead cells. Total live cell number was graphed and
analysed using Graph Pad Prism 5.0. Prior to each in vivo
experiment, the percentage of cells containing iron oxide was
determined with a hemocytometre using light microscopy. For
injection in vivo, iron-loaded and non iron-loaded cells were treated
with Accutase, collected, centrifuged, and re-suspended at a
concentration of 2610
6 cells/mL in Hanks balanced salt solution
(HBSS). Cells were kept at 4uC until they were injected, a
maximum of 2 hours later.
MRIgFUS
Animals were anesthetised with ketamine (50 mg/kg) and
xylazine (10 mg/kg) and depilatory cream was used to remove
hair from the head. Animals were placed supine on a custom-built
FUS positioning system with their heads coupled to a degassed
water bag and the entire system was placed in the 1.5T MR
scanner (GE Healthcare). Baseline T1-weighted (TE= 10 ms,
TR=500 ms) and fast gradient echo (FGRE) sequences
(TE=20 ms, TR=30 ms, NEX=2, flip angle=30u, slice thick-
ness=1 mm, matrix=2566256) in addition to baseline T2-
weighted (TE=60 ms, TR=2000 ms) images in all 3 planes
(coronal, axial and sagittal) were acquired. The T2 images were
used to choose 4 precise target points, creating a 1 mm square in
each of the striatum and hippocampus. DefinityH microbubble
contrast agent (0.2 mg/kg, Lantheus Medical) was injected
through a tail vein catheter immediately prior to sonications.
Sonications were completed using a 558 kHz transducer
(0.24 MPa estimated in situ pressure, 10 ms bursts, 1 Hz pulse
repetition frequency, 120 s total exposure duration) according to
Jorda ˜o et al [16]. Opening of the BBB was confirmed on a
T1-weighted image after injection of an MRI contrast agent
(Omniscan, 0.2 mL/kg) through the tail vein. Following BBB
opening, the plug from the carotid artery catheter was removed and
flushed with 0.5 mL of heparinised saline and then allowed to bleed
back from the catheter. Neural stem cells, suspended in 1 mL of
HBSS as described above, were injected into the carotid artery
catheter followed by 1 mL of saline flush. Animals were sacrificed
either 4 or 24 hours after sonication. Animals which were given
iron-loaded stem cells (n=6), were re-imaged 15 and 60 min after
sonication. FGRE sequences were used to identify disturbances in
the MR images indicative of entry of iron-loaded cells.
Immunohistochemistry
Rats were deeply anesthetised with ketamine/xylazine and
perfused intracardially with saline, followed by 10% formalin.
Brains were removed, post-fixed overnight and equilibrated in
30% sucrose. Coronal sections were cut at 50 mm from the
beginning of the striatum through the hippocampus. Serial
sections were collected in 24 well plates filled with cryoprotectant.
Sections were processed using standard immunohistochemistry
procedures [26]. Mouse monoclonal anti-nestin (1:200; Millipore),
rabbit anti-GFP (1:400; AbCAM), goat anti-doublecortin (1:400;
Santa Cruz Biotechnology), rabbit anti-GFAP (1:4000; Dako),
mouse monoclonal anti-PSA (1:1000, generously provided by Dr.
Tatsunori Seki) were applied overnight at 4uC in phosphate
buffered saline containing 5% donkey serum and 0.5% Triton X-
100. Sections were then incubated with appropriate secondary
antibodies (Jackson ImmunoResearch) for 2 hours at room
temperature and coverslipped with Vectashield hard-set mounting
media (Vector Laboratories). Cells plated in vitro were cultured for
24 hours and fixed with methanol for 10 min and then processed
as described above.
To identify red blood cell extravasation, brains were routinely
processed for paraffin-wax embedding, cut into 4 mm sections and
stained with Hematoxylin & Eosin (H&E). To confirm the
immunohistochemistry results, sequential 4 mm sections were
stained with anti-nestin and anti-GFP antibodies using Vector
ImmPRESS staining kits and visualized with 3,39-diaminobenzi-
dine.
Analysis
Analysis of MR images was performed in MATLAB (The
MathWorks, Natick, MA, USA). Enhancement of the sonication
locationsrelative to baseline wasaveraged over a 262 mm regionof
interest. The region of interest was selected based on the maximum
enhancement observed over a series of contrast-enhanced T1-
weighted images. Fluorescent images were collected from thin
optical sections throughout the thickness of the tissue using a Zeiss
Axiovert confocal laser scanning microscope 510 with a 206and
636objectives. Figure montages were created in Adobe Photoshop
7.0 (Adobe Systems Inc, San Jose CA, USA). Stem cells were
quantified by counting the number of GFP positively stained cells in
a1m m 61 mm region of interest in coronal sections. We analyzed
the section determined to be at the centre of the sonication location
(n=8). The same region was examined in the contralateral
hemisphere in the same coronal section.
Supporting Information
Figure S1 Iron-oxide labeling does not affect cell
survival, proliferation or differentiation. A) One million
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absence of 5 mg superparamagnetic iron oxide (n=3). Cells were
counted at 24 and 48 hours using Trypan blue to exclude dead
cells. Total cell counts and rate of proliferation were unchanged by
the incorporation of iron into the cells. Data was analyzed using
Graph Pad Prism. B) After 24 hours in culture, cells were fixed
with methanol for 10 min at room temperature. Standard
immunohistochemistry was performed and images were taken
with confocal microscopy. GFP-positive cells (left panel) were
stained for mouse anti-nestin-Cy3 (middle panel) and the overlay
(right panel) shows colocalization demonstrating the stem cells
express nestin in vitro. Similar results were obtained using anti-
polysialic acid.
(TIF)
Table S1 T1 weighted enhancement levels confirm BBB
opening by FUS. Contrast enhanced T1 weighted MR images
were analyzed using MATLAB. Enhancement of the sonication
locations was averaged over a 262 mm region of interest in the
image showing maximum enhancement. The level of enhance-
ment was compared to the same region in the opposite (non-
sonicated) hemisphere.
(PDF)
Acknowledgments
We would like to thank Dr. Tatsunori Seki for the generous donation of the
mouse monoclonal PSA antibody. We would like to acknowledge Shawna
Rideout-Gros and Alexandra Garces for their help with animal care. We
would also like to thank Adam Waspe and Yuexi Huang for assistance with
the MRI and Ping Wu for assistance with FUS.
Author Contributions
Conceived and designed the experiments: AB CAG MG JFJ IA KH.
Performed the experiments: AB CAG MG. Analyzed the data: AB CAG.
Contributed reagents/materials/analysis tools: IA KH. Wrote the paper:
AB IA KH.
References
1. Go ¨gel S, Gubernator M, Minger SL (2011) Progress and prospects: stem cells
and neurological diseases. Gene Ther 18: 1–6.
2. Rossi F, Cattaneo E (2002) Neural stem cell therapy for neurological disorders:
dreams and reality. Nature Reviews Neurosci 3: 401–409.
3. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, et al. (1994)
Evidence for long-term survival and function of dopaminergic grafts in
progressive Parkinson’s disease. Annals of Neurology 35: 172–180.
4. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, et al. (1990)
Science 247: 574–577.
5. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, et al. (1997) Short-
and long-term survival and function of unilateral intrastriatal dopaminergic
grafts in Parkinson’s disease. Annals of Neurology 42: 95–107.
6. Yasuhara R, Matsukawa N, Hara K, Yu G, Xu L, et al. (2006) Transplantation
of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s
disease. J Neurosci 26: 12497–12511.
7. Chuang CS, Su HI, Cheng FC, Hsu SH, Chuang CF, et al. (2010) Quantitative
evaluation of motor function before and after engraftment of dopaminergic
neurons in a rat model of Parkinson’s disease. J Biomed Sci 17: 9–18.
8. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Mu ¨ller FJ, et al.
(2009) Neural stem cells improve cognition via BDNF in a transgenic model of
Alzheimer’s disease. Proc Natl Acad Sci USA 106: 13594–13599.
9. Perry VH, Andersson PB, Gordon S (1993) Macrophages and inflammation in
the central nervous system. Trends Neurosci 16: 268–273.
10. Sinden JD, Patel SN, Hodges H (1992) Neural transplantation: problems and
prospects for therapeutic application. Curr Opin Neurol Neurosurg 5: 902–908.
11. Danielyan L, Scha ¨fer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S,
et al. (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem
cells in a rat model of Parkinson disease. Rejuvenation Res 14: 3–16.
12. Seyfried DM, Han Y, Yang D, Ding J, Savant-Bhonsale S, et al. (2008) Mannitol
enhances delivery of marrow stromal cells to the brain after experimental
intracerebral hemorrhage. Brain Res 11: 1224–1229.
13. Hynynen K (2008) Ultrasound for drug and gene delivery to the brain. Adv
Drug Deliv Rev 60: 1209–1217.
14. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR
imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology
220: 640–646.
15. Kinoshita M, McDannold N, Jolesz FA, Hynynen K (2006) Noninvasive
localized delivery of Herceptin to the mouse brain by MRI-guided focused
ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA
103: 11719–11723.
16. Jorda ˜o JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, et al. (2010)
Antibodies targeted to the brain with image-guided focused ultrasound reduces
amyloid-b plaque load in the TgCRND8 mouse model of Alzheimer’s disease.
Plos One 5: 1–8.
17. Bulte JWM, Douglas T, Witwer B, Zhang S-C, Strable E, et al. (2001)
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of
stem cells. Nature Biotechnol 19: 1141–1147.
18. Seki T, Namba T, Mochuizuki H, Onodera M (2007) Clustering, migration and
neurite formation of neural precursor cells in the adult rat hippocampus. J Comp
Neurol 502: 275–290.
19. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR (2004) Central nervous
system entry of peripherally injected umbilical cord blood cells is not required for
neuroprotection in stroke. Stroke 35: 2385–2389.
20. McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K (2005)
MRI-guided targeted blood-brain barrier disruption with focused ultrasound:
Histological findings in rabbits. Ultrasound Med Biol 31: 1527–1537.
21. Matsushita T, Kibayashi T, Katayama T, Yamashita Y, Suzuki S, et al. (2011)
Mesenchymal stem cells transmigrate across brain microvascular endothelial cell
monolayers through transiently formed inter-endothelial gaps. Neuroscience
Lett 502: 41–46.
22. Bulte JW, Kraitchman DL (2004) Monitoring cell therapy using iron oxide MR
contrast agents. Curr Pharm Biotechnol 5: 567–584.
23. O’Reilly MA, Waspe AC, Ganguly M, Hynynen K (2011) Focused-ultrasond
disruption of the blood-brain barrier using closely-timed short pulses: influence
of sonication parameters and injection rate. Ultrasound Med Biol 37: 585–594.
24. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, et al. (2008)
Dual-modality monitoring of targeted intraarterial delivery of mesenchymal
stem cells after transient ischemia. Stroke 39: 1569–1574.
25. Nelson PT, Kondziolka D, Wechsler L, Goldstein S, Gebel J, et al. (2002) Clonal
human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27
months after implantation. Am J Pathol 160: 1202–1206.
26. Burgess A, Wainwright SR, Shihabuddin LS, Rutishauser U, Seki T, et al.
(2008) Polysialic acid regulates the clustering, migration and neuronal
differentiation of progenitor cells in the adult hippocampus. Dev Neurobiol
68: 1580–1590.
Stem Cell Delivery Using MRIgFUS
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27877